Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Phase 3

Completed

• Conditions: Attention Deficit Disorder

• Registration Number: NCT00048360
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Detailed Description

Not available

Study Timeline

• Study Start: 2002-10
• Study First Submitted: 2002-10-30
• Study First Submitted QC: 2002-10-30
• Study First Posted: 2002-10-31
• Primary Completion: 2003-06
• Study Completion: 2003-06
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-11
• Last Update Posted: 2013-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 162

Inclusion Criteria

Not provided

Exclusion Criteria

• Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
• Patient has a current diagnosis of Major Depressive Disorder (MDD).
• Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
• Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
• Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
ADHD Rating Scale

Secondary Outcome Measures

Name	Time	Method
Clinical Global Impressions -Severity and Improvement.
Quality of Life Enjoyment and Satisfaction Questionnaire.

Trial Locations

Locations (1)

GSK Clinical Trials Call Center; 🇺🇸 Seattle, Washington, United States